We are analyzing https://link.springer.com/article/10.1007/s11912-004-0022-5.

Title:
Mammalian target of rapamycin (mTOR) inhibitors | Current Oncology Reports
Description:
Current efforts in anticancer drug development are targeting key factors in cell-cycle regulation. Mammalian target of rapamycin (mTOR) is one such protein kinase that facilitates cell growth by stimulating the cell to traverse the G1 to S phase of the cell cycle. Rapamycin is the first defined inhibitor of mTOR, and the demonstration of its antitumor activity has led to great interest in this pathway as an antitumor mechanism. Analogues with better pharmacologic properties have been developed and have entered clinical trials. Human cell lines of renal cell cancer, among several other tumors, are sensitive to growth inhibition via this pathway. Ongoing clinical trials are evaluating renal cell cancer and other malignancies using therapy with mTOR inhibitors. These agents are more likely to induce growth inhibition rather than tumor regression.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

google, scholar, cancer, article, pubmed, cas, rapamycin, mtor, cell, cci, abstract, growth, phase, renal, inhibition, proc, study, target, res, antitumor, therapy, privacy, cookies, content, inhibitor, pathway, human, tumors, tumor, access, cells, hypoxiainducible, patients, asco, publish, search, mammalian, inhibitors, dutcher, regulation, breast, hippellindau, intravenous, advanced, carcinoma, data, information, log, journal, research,

Topics {✒️}

11th nci-eortc-aacr symposium renal cell carcinoma month download article/chapter von hippel-lindau mutation prolonged disease-free survival von hippel-lindau protein broad anti-tumor activity renal cell cancer human renal cancer pten/pi3 kinase pathways targeting key factors tumor growth inhibition targeting mtor signaling human tumor cells full article pdf human cell lines hypoxia-inducible factors hypoxia-inducible genes privacy choices/manage cookies facilitates cell growth related subjects pten-deficient tumors induce growth inhibition taxane regimens [abstract] clinical development [abstract] cell-cycle regulation mercy cancer center article dutcher check access instant access european economic area anticancer drug development entered clinical trials ongoing clinical trials potential future indication anti-fungal antibiotic multiple myeloma cells nude mouse xenograft wild-type cells long term follow locally advanced long-term follow 8th annual meeting york medical college mammalian target conditions privacy policy confers rapamycin resistance cell cycle accepting optional cookies rapamycin-sensitive pathway

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mammalian target of rapamycin (mTOR) inhibitors
         description:Current efforts in anticancer drug development are targeting key factors in cell-cycle regulation. Mammalian target of rapamycin (mTOR) is one such protein kinase that facilitates cell growth by stimulating the cell to traverse the G1 to S phase of the cell cycle. Rapamycin is the first defined inhibitor of mTOR, and the demonstration of its antitumor activity has led to great interest in this pathway as an antitumor mechanism. Analogues with better pharmacologic properties have been developed and have entered clinical trials. Human cell lines of renal cell cancer, among several other tumors, are sensitive to growth inhibition via this pathway. Ongoing clinical trials are evaluating renal cell cancer and other malignancies using therapy with mTOR inhibitors. These agents are more likely to induce growth inhibition rather than tumor regression.
         datePublished:2004-04-01T00:00:00Z
         dateModified:2004-04-01T00:00:00Z
         pageStart:111
         pageEnd:115
         sameAs:https://doi.org/10.1007/s11912-004-0022-5
         keywords:
            Rapamycin
            mTOR Inhibition
            Renal Cell Cancer
            Primary Brain Tumor
            Advanced Renal Cell Carcinoma
            Oncology
         image:
         isPartOf:
            name:Current Oncology Reports
            issn:
               1534-6269
               1523-3790
            volumeNumber:6
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Janice P. Dutcher
               affiliation:
                     name:New York Medical College
                     address:
                        name:Our Lady of Mercy Cancer Center, New York Medical College, Bronx, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mammalian target of rapamycin (mTOR) inhibitors
      description:Current efforts in anticancer drug development are targeting key factors in cell-cycle regulation. Mammalian target of rapamycin (mTOR) is one such protein kinase that facilitates cell growth by stimulating the cell to traverse the G1 to S phase of the cell cycle. Rapamycin is the first defined inhibitor of mTOR, and the demonstration of its antitumor activity has led to great interest in this pathway as an antitumor mechanism. Analogues with better pharmacologic properties have been developed and have entered clinical trials. Human cell lines of renal cell cancer, among several other tumors, are sensitive to growth inhibition via this pathway. Ongoing clinical trials are evaluating renal cell cancer and other malignancies using therapy with mTOR inhibitors. These agents are more likely to induce growth inhibition rather than tumor regression.
      datePublished:2004-04-01T00:00:00Z
      dateModified:2004-04-01T00:00:00Z
      pageStart:111
      pageEnd:115
      sameAs:https://doi.org/10.1007/s11912-004-0022-5
      keywords:
         Rapamycin
         mTOR Inhibition
         Renal Cell Cancer
         Primary Brain Tumor
         Advanced Renal Cell Carcinoma
         Oncology
      image:
      isPartOf:
         name:Current Oncology Reports
         issn:
            1534-6269
            1523-3790
         volumeNumber:6
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Janice P. Dutcher
            affiliation:
                  name:New York Medical College
                  address:
                     name:Our Lady of Mercy Cancer Center, New York Medical College, Bronx, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Oncology Reports
      issn:
         1534-6269
         1523-3790
      volumeNumber:6
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:New York Medical College
      address:
         name:Our Lady of Mercy Cancer Center, New York Medical College, Bronx, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Janice P. Dutcher
      affiliation:
            name:New York Medical College
            address:
               name:Our Lady of Mercy Cancer Center, New York Medical College, Bronx, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Our Lady of Mercy Cancer Center, New York Medical College, Bronx, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(77)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.56s.

LINK . SPRINGER . COM {}